Miruvor
ME/CFS No benefit

Plaquenil for ME/CFS: work for anybody?

Condition
ME/CFS
At worst
Not stated
Ill for
Not stated
Published
Aug 2018

Summary

Hydroxychloroquine was taken for four months by an ME/CFS patient with no dose specified. The account states only that it did absolutely nothing for their symptoms. No illness duration, severity, or side effects are given. There is no report of any benefit, relapse, or follow-up beyond the four-month trial.

Read it in their words

forums.phoenixrising.me

What they credit

Credits Hydroxychloroquine / Plaquenil.

Similar stories

  • Long-Term Daily mHBOT and Full Recoveries w/ Ongoing Maintenance

    Substantial ME/CFS Moderate forums.phoenixrising.me Jul 2020

    used_to_race combined daily hydroxychloroquine with mHBOT sessions 3-4 times a week for 45-90 minutes, plus fludrocortisone for POTS, and reported bad days becoming much less frequent, with capacity for 76-mile cycling weekends and full-time work plus…

  • The Temporary Recovery Stories (Judith)

    Relapsed ME/CFS Ill 30 yearsEffect faded healthrising.org Jan 2020

    Commenter Judith described multiple remissions and relapses since childhood, including a Rituximab course that caused complications. She now manages with AHCC, magnesium, Plaquenil and colchicine, and describes the illness as progressive, each relapse…

  • Plaquenil for ME/CFS: work for anybody?

    Substantial ME/CFS Moderate forums.phoenixrising.me Oct 2018

    Hydroxychloroquine at 400mg daily, started August 2018, brought substantial improvement within about two months. Before starting, symptoms were borderline mild-to-moderate ME/CFS with POTS-like dysautonomia, frequent GI symptoms, headaches and rashes. After…

  • Plaquenil for ME/CFS: work for anybody?

    Substantial ME/CFS Severe forums.phoenixrising.me Aug 2018

    Hydroxychloroquine, started at 200mg daily and increased to 200mg twice daily, was taken for about 18 months after being prescribed for an autoimmune skin condition (granuloma annulare). The person had severe ME at baseline and described the drug as…